Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 06, 2018 16:30 ET | Source: Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif. , Nov. 06, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that the Company will participate in the following investor conferences...
November 01, 2018 17:30 ET | Source: Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) announced today that on October 26, 2018, the Compensation Committee of the Board of...
November 01, 2018 16:03 ET | Source: Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals to Present New Interim Phase 2 Results for Cerdulatinib During an Oral Session at the 60th American Society of Hematology (ASH) Annual Meeting

– Differentiated Syk/JAK Inhibitor Studied in Patients with Heavily Pre-Treated T-Cell Malignancies – – Also Accepted: Two Posters on Andexxa® and an Oral Session on the Burden of...
October 23, 2018 08:30 ET | Source: Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals to Announce Third Quarter 2018 Financial Results and Host Conference Call on Wednesday, November 7, 2018

SOUTH SAN FRANCISCO, Calif., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that it will host a webcast and conference call to discuss the Company’s...
October 09, 2018 09:05 ET | Source: Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals Supports 2018 World Thrombosis Day Campaign to Raise Awareness of Blood Clots as an Urgent and Growing Health Crisis

SOUTH SAN FRANCISCO, Calif., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced its 2018 partnership with the World Thrombosis Day campaign to help raise...
September 25, 2018 16:38 ET | Source: Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals Receives FDA Orphan Drug Designation for Cerdulatinib, an Oral Syk/JAK Inhibitor for the Treatment of Peripheral T-Cell Lymphoma

SOUTH SAN FRANCISCO, Calif., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq: PTLA) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug...
September 20, 2018 08:30 ET | Source: Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals Names Scott Garland President and Chief Executive Officer

– Relypsa president and former Exelixis chief commercial officer brings significant commercial and operational expertise – – Commercial responsibility for two of the industry’s most successful...
September 11, 2018 18:06 ET | Source: Portola Pharmaceuticals, Inc.

U.S. FDA Assigns PDUFA Date to Portola Pharmaceuticals’ Prior Approval Supplement for the Large-Scale Generation 2 Andexxa Process

SOUTH SAN FRANCISCO, Calif., Sept. 11, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt...
September 07, 2018 08:30 ET | Source: Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals Announces Executive Leadership Change

SOUTH SAN FRANCISCO, Calif., Sept. 07, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that Tao Fu, chief commercial officer, has resigned effective September...
September 05, 2018 18:15 ET | Source: Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) announced today that on August 31, 2018, the Compensation Committee of the Board of...